News, Short Squeeze, Breakout and More Instantly...
- In Vivo Model Developed by Dyne Sets New Standard for Evaluating Pharmacodynamics in DM1 - - Preclinical Data Further Validate FORCE™ Platform; IND Submissions Planned for DM1, DMD and FSHD Programs Between Q4’21 and Q4’22 - WALTHAM, Mass., Jan. 10...
WALTHAM, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that Joshua Brumm, president and chief ex...
BOSTON, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Cerevance, a private drug discovery and development company focused on brain diseases, today announced the appointment of David Lubner, a senior finance executive with more than 25 years of experience in the life sciences industry, to Cerevance ...